Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 7/20 | 0.50 |
| ▸ | EPRS1 | P07814 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15905102 | 0.86 | EPRS1 (0.64) | ALDH1A1GAADHODHEPRS1MEN1 | |
| SCHEMBL4252230 | 0.83 | ALDH1A1 (0.69) | ALDH1A1GAADHODHMEN1KMT2A | |
| SCHEMBL15919487 | 0.82 | DHODH (0.53) | ALDH1A1GAADHODHMEN1KMT2A | |
| SCHEMBL15919376 | 0.81 | ACACB (0.43) | ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL4254130 | 0.80 | ALDH1A1 (0.61) | ALDH1A1GAADHODHMEN1KMT2A | |
| SCHEMBL4251041 | 0.79 | KDM4E (0.69) | ALDH1A1GAADHODH | |
| SCHEMBL4247643 | 0.78 | ALDH1A1 (0.66) | ALDH1A1GAADHODH | |
| SCHEMBL4248489 | 0.78 | DHODH (0.64) | ALDH1A1GAADHODH | |
| SCHEMBL4251010 | 0.78 | DHODH (0.61) | ALDH1A1GAADHODH | |
| SCHEMBL4245149 | 0.76 | KDM4E (0.64) | ALDH1A1GAADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ALDH1A1 289/4885GAA 6/4885DHODH 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.